glp-1 obesity drug news today october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care Harnessing GLP-1 Receptor Agonists for
Description
Avogaro A, Fadini GP
The availability of semaglutide in different formulations, such as injections and oral tablets, provides patients with options that cater to their preferences
Last month, Lilly announced that orforglipron, an orally available GLP-1 treatment, significantly lowered blood glucose levels in patients with type 2 diabetes
They can also watch for rarer, more dangerous risks, such as gallbladder inflammation, gallstones, and pancreatitis
[DOI] [PubMed] [Google Scholar] Aspnes G
